Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Gideon M. Hirschfield, David Sheridan et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 186
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 studyCynthia Levy, Alexandra Steinberg, Christopher L. Bowlus et al.|Journal of Hepatology|2020Cited by 10
Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 studyGideon M. Hirschfield, DE Jones, Pol Boudes et al.|Journal of Hepatology|2018Cited by 5
Proof of efficacy for Seladelpar, a selective PPAR-δ agonist, in patients with primary biliary cholangitis non-responsive to ursodeoxycholic acid: results of an international Phase 2 randomised controlled clinical studyGideon M. Hirschfield, DE Jones, Michal Galamboš et al.|Journal of Hepatology|2017Cited by 1
686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDYAndreas E. Kremer, Yun‐Jung Choi, Marlyn J. Mayo et al.|Gastroenterology|2020Cited by 1